Parkside Financial Bank & Trust Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Parkside Financial Bank & Trust lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 16,979 shares of the company’s stock after selling 684 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Parkside Financial Bank & Trust’s holdings, making the stock its 22nd largest holding. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,774,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of JNJ. Morton Brown Family Wealth LLC lifted its position in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $39,000. Cardinal Capital Management Inc. lifted its position in Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust lifted its position in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock worth $40,960,735 in the last three months. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Morgan Stanley cut their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Raymond James cut their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, SVB Leerink cut their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Tuesday. The company has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The business has a 50 day simple moving average of $176.07 and a 200-day simple moving average of $171.13. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.